Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Context Therapeutics Inc.NASDAQ: CNTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$8.64M, compared with -$4.57M a year earlier. Trailing-twelve-month EBITDA was -$40.18M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -35.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.64M+33.6% QoQ
- Last fiscal yearDec 2025
- -$36.11M-35.2% YoY
- LTMMar 2026
- -$40.18M-45.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -89.0% | +100.0% | +189.0 pp |
| 1 year | -35.2% | +100.0% | +135.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (36.11M) USD
- Year-over-year change
- -35.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (36.11M) | -35.2% |
| FY2024 | 2024-12-31 | (26.71M) | -11.5% |
| FY2023 | 2023-12-31 | (23.95M) | -61.1% |
| FY2022 | 2022-12-31 | (14.87M) | -99.9% |
| FY2021 | 2021-12-31 | (7.44M) | — |
EBITDA vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.5% is the 9th highest of 11, against a peer median of -2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M USD | +1391.3% | — | — | |
| LTM Mar 2026 | -$24M USD | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$29.2M USD | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M USD | +36.5% | — | — |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
IMAImageneBio Inc | LTM Mar 2026 | -$51.64M USD | -7.8% | — | — |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M USD | -490.7% | — | — |
| Peer median (excluding CNTX) | — | -2.7% | — | 13207.8% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| Weighted Avg Shares | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
| Weighted Avg Shares (Diluted) | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.